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Abstract 
Osteoclasts are defined as cells capable of excavating 3-dimensional resorption pits in bone, 
and other mineralised tissues.   They derived from the differentiation / fusion of 
promonocytic precursors, and are usually large, multinucleated cells.   In common with 
other cells from this myeloid lineage such as macrophages and dendritic cells, they are 
adapted to function in hypoxic, acidic environments.  The process of bone resorption is 
rapid and appears to be highly energy-intensive, since osteoclasts must actively extrude 
protons to dissolve hydroxyapatite mineral, whilst secreting cathepsin K to degrade 
collagen, as well as maintaining a high degree of motility.  Osteoclasts are well known to 
contain abundant mitochondria but they are also able to rely on glycolytic (anaerobic) 
metabolism to generate the ATP needed to power their activity.  Their primary extracellular 
energy source appears to be glucose.  Excessive accumulation of mitochondrial reactive 
oxygen species in osteoclasts during extended periods of high activity in oxygen-poor 
environments may promote apoptosis and help to limit bone resorption - a trajectory that 
could be termed ‘live fast, die young’.   In general, however, the metabolism of osteoclasts 
remains a poorly-investigated area, not least because of the technical challenges of studying 
actively resorbing cells in appropriate conditions.   
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Introduction 
Osteoclasts are bone-resorbing cells that are derived from promonocytic precursors present 
in marrow, spleen and circulating blood [67,68,16]; they are considered to be terminally 
differentiated cells that are incapable of self-replication.  Osteoclasts excavate 
characteristic, scalloped pits and troughs in bone, dentine and other mineralised tissues by 
secreting acid and proteolytic enzymes (chiefly cathepsin K) into a sealed extracellular 
compartment to dissolve the mineral and collagenous organic matrix components, 
respectively. 
Bone resorption by osteoclasts normally proceeds much more rapidly than bone formation 
by osteoblasts.  In vitro, continuous resorption trails or fields are commonly observed when 
osteoclasts are formed on bone or dentine from marrow or blood precursor cells using 
MCSF and RANKL and exposed to the acidic conditions required for activation [51,7] (Fig 1).   
Activation of osteoclasts involves cell polarisation, with formation of a prominent ruffled 
border (Figs 1 & 2) and markedly increased expression of the machinery of bone resorption, 
including carbonic anhydrase 2, the vacuolar-type H+ ATPase (v-ATPase), cathepsin K and 
tartrate-resistant acid phosphatase (TRAP).   An activated osteoclast in vitro can resorb an 
estimated quantity of mineralised matrix equivalent to about twice its own volume per day 
[7].  This impressive work rate suggests that resorbing osteoclasts have high energetic 
requirements. 
In addition to their clearly-defined state of activation, osteoclasts exhibit a number of other 
special features of interest with respect to energy metabolism.   These include cell fusion 
and multinuclearity, abundant mitochondria (Fig 2), a high degree of cell motility, 
intracellular trafficking of waste products from resorption, the ability to function in both 
oxygenated and hypoxic environments, and susceptibility to apoptosis.  Energy metabolism 
in osteoclasts has not been extensively investigated, particularly during the process of 
resorption pit formation.  However, it is clear that osteoclasts display remarkable metabolic 
adaptability, reflecting the properties of their related cells in the monocytes / macrophage 
lineage [61]. 
This brief review discusses what is known of the metabolic characteristics of osteoclasts 
during the distinct phases of their lives: formation, activation and death. 
 
Hypoxia and osteoclasts 
Before discussing current knowledge of key pathways in osteoclast metabolism, it is worth 
considering a remarkable property of these cells, namely their responses to changes in 
ambient oxygen tension. 
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In most normal, resting tissues, oxygen tension (pO2) is generally thought to be between 
about 90 mmHg (~12%) and 40 mmHg (~5%), the respective values for arterial and venous 
blood.  The skeleton appears to be unusual in that it contains various hypoxic environments, 
as demonstrated by independent methods.  For example, mean pO2 values of 6.6% have 
been reported for bone marrow aspirates from normal human donors [21], whereas direct 
imaging measurements of pO2 in the calvariae of live, young adult mice yielded the 
surprisingly low values of 6.3%, 3.9% and 1.5-2.5 % in periosteum, cortical bone and 
marrow, respectively [60].  An important corollary of these in vivo observations is that in 
vitro investigations of osteoclast function and metabolism performed in atmospheric oxygen 
(pO2 = 21%, which is commonly considered to represent ‘normoxia’) are actually conducted 
in significantly hyperoxic conditions that constitute a 3 to 10-fold excess of oxygen, with 
respect to the physiological environment in bone.   Pathological hypoxia in bone could result 
from numerous causes including inflammation, tumours, diabetes, anaemias, fractures and 
ageing [6]. 
Hypoxia was shown to strikingly increase the number and size of osteoclasts formed in 
cultures of RANKL/M-CSF-treated mouse marrow cells on ivory discs, resulting in large 
increases in resorption pit formation.  Hypoxia also caused maximal increases in osteoclastic 
resorption in bone organ cultures of mouse calvariae.  Optimal osteoclast formation 
occurred in 1-2% O2 but osteoclastogenesis was elevated even in cultures gassed with 0.2% 
O2, compared with 20% O2 [5].  Comparable findings have been reported in other studies 
using human [31,65,48] and cat [46] osteoclasts.  The resorptive function of osteoclasts was 
unaltered in pH-controlled, hypoxic conditions.  This indicates that the primary action of 
hypoxia is to increase osteoclastogenesis, and that the increased resorption observed in 
hypoxic cultures reflects the presence of increased numbers of larger osteoclasts, rather 
than increases in their activity (which might result from hypoxia-induced acidification).   
However, osteoclast survival was significantly reduced in cultures exposed to severe and/or 
continuous hypoxia [5,31,65].  Periodic re-oxygenation (eg, at culture medium changes) is 
required for optimal osteoclastogenesis and survival, and the possibility cannot be excluded 
that it is re-oxygenation rather than hypoxia which primarily drives osteoclastogenesis [22].  
Fluctuating, non-uniform oxygen levels may well reflect the in vivo microenvironments 
experienced by differentiating osteoclasts more accurately than steady state hypoxia 
[5,6,65,32,27].  The effect of hypoxia on osteoclastogenesis appears to reflect the trophic 
actions of low pO2 on macrophage differentiation [26,9,33,61].  These findings may help 
explain why extravasation of monocytic precursors into relatively oxygen-deficient bone 
microenvironments could help drive osteoclast formation, and offer potential insights into 
the bone loss associated with the pathological hypoxia.   
In contrast to the stimulatory effect of hypoxia on osteoclastogenesis, exposure to 
atmospheric oxygen levels (20% O2) markedly inhibited formation of mouse and human 
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osteoclasts, with respect to 2-5% O2, which roughly equates to average pO2 values in 
extracellular environments of living bone [5,65].  Severe hyperoxia (95% - 100% O2), both in 
vitro and in vivo, is reported to cause further inhibition of osteoclastogenesis, in comparison 
with atmospheric pO2 [19,20].   Conversely, osteoblast function and bone formation are 
oxygen-dependent processes that are inhibited by hypoxia [64,6]. 
 
Glycolytic and oxidative metabolism in osteoclasts 
General principles 
In common with almost all animal cells, osteoclasts can generate ATP by both glycolysis and 
oxidative phosphorylation.   Glycolysis is the cytosolic, oxygen-independent metabolic 
pathway that rapidly converts a molecule of glucose into pyruvate, releasing free energy 
that is used to generate 2 molecules of ATP.  In the absence of oxygen, pyruvate is generally 
metabolised to lactate.   When oxygen is present, pyruvate may theoretically be fully 
metabolised to CO2 in the mitochondria via the tricarboxylic acid cycle, generating a 
potential maximum of 34 further molecules of ATP (Fig 3) [29].   Aerobic respiration is thus a 
far more effective way to generate energy than glycolysis.   However, multiple cell types, 
including osteoblasts appear to metabolise glucose into lactate, even in the presence of 
sufficient oxygen, a process known as aerobic glycolysis. 
Glycolytic metabolism of one glucose molecule yields 2 H+, whereas its complete 
mitochondrial oxidation to CO2 produces 6 H
+.  Therefore, glycolysis theoretically generates 
6 times more H+ than oxidative phosphorylation per ATP molecule created [43].  This has 
potentially important consequences for the activation of osteoclastic resorption in hypoxic 
bone microenvironments subject to acidification due to glycolytic metabolism of resident 
(mainly non-osteoclastic) cells [6]. 
Mitochondria 
It has long been recognised that osteoclasts contain plentiful mitochondria [12,15] (Fig 2).   
However, the biogenesis and function of mitochondria in osteoclasts has been relatively 
little studied.  Estimates of mitochondrial mass in human osteoclasts suggest that they 
retain the mitochondria of their precursor cells [39], although increased expression of 
mRNAs for mitochondrial genes such as respiratory complexes I–V has been described 
during the formation of mouse osteoclasts [25].   Mitochondrial biogenesis in osteoclasts is 
reported to be regulated by peroxisome proliferator–activated receptor-c coactivator 1β 
(PGC-1β) and iron uptake (required for mitochondrial respiratory proteins), via the 
transferrin 1 receptor [25].   A subsequent study from another group obtained somewhat 
divergent results.   Mitochondrial biogenesis was shown to be stimulated by RANKL but was 
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not affected by PGC-1β overexpression.  Inactivating mutations in the NF-B pathway 
proteins, RelB and NF-kB–inducing kinase (NIK) blocked bone resorption and the stimulatory 
action of RANKL on mitochondrial DNA, the expression of proteins related to oxidative 
phosphorylation and oxygen consumption [71].   
The underlying reasons for the numerous mitochondria in osteoclasts are not entirely clear.  
One possibility is that they presumably help the cell to recover quickly following re-
oxygenation after a high work rate in hypoxic conditions.  A further explanation for the 
mitochondrial abundance may lie in their key role in the intrinsic apoptotic signalling 
pathway.  Mitochondria act as a reservoir of pro-death factors, notably cytochrome c and 
Smac/DIABLO, which are released through stress-induced membrane pores to activate the 
caspase pathway [55].   Osteoclasts are well-known to be susceptible to apoptosis, and the 
triggering of apoptosis by mitochondria may constitute an effective mechanism for rapidly 
eliminating these highly destructive cells. 
Metabolism in differentiating and activated osteoclasts 
An early cytophotometric study of fresh human bone sections showed that osteoclasts 
associated with bone surfaces (and thus more likely to be actively resorbing) displayed a 
high capacity for the (mitochondrial) β-oxidation of fatty acids, a highly efficient energy 
source.  In contrast, such osteoclasts were observed to be deficient in the enzymes 
associated with glycolysis and the anabolic pentose shunt pathway [14].  
Subsequent metabolic investigations have relied on osteoclasts cultured in vitro.   A study 
using multinucleated cells purified from the bones of egg laying hens provided the first 
direct evidence that D-glucose was the principal energy source for osteoclasts.  Glucose 
consumption was shown to double when these osteoclast-like cells were in contact with 
(and degrading) powdered bone particles; lactate was also able to support bone 
degradation to a small extent [69].  Subsequent work showed that extracellular glucose 
upregulated mRNA for the v-ATPase [35] and quickly increased the intracellular ratio of ATP 
to ADP in the avian osteoclast-like cells [36].   Supraphysiological glucose concentrations of 
glucose inhibit osteoclastogenesis [70]. 
Studies with osteoclasts formed from mouse marrow cells on plastic (ie, non-resorbing cells) 
showed that RANKL treatment resulted in increased lactate production, via upregulation of 
lactate dehydrogenase and glucose utilisation, along with large increases in oxygen 
consumption, as well as significant extracellular acidification [30,1].  These findings suggest 
that both aerobic and anaerobic respiration occur during osteoclastogenesis.   The same 
group also found that rotenone, an inhibitor of mitochondrial complex 1, strongly decreased 
in vitro osteoclastogenesis, together with the expression of mRNAs for key osteoclast-
related factors such as c-Fos, NFATc1, TRAP and OSCAR [30].  Rotenone was subsequently 
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shown to block resorption pit formation in vitro and reduce LPS-induced bone loss in vivo 
[34].  The above findings contrast somewhat with a subsequent investigation which found 
that osteoclastogenesis was associated with increased expression of glycolytic genes, 
including hexokinase, phosphofructokinase and pyruvate kinase [24].  This study also 
reported increased expression of both glucose and glutamine transporters during osteoclast 
differentiation, and that depletion of glucose or L‐glutamine suppressed osteoclast 
differentiation and function. 
A recent study of osteoclasts derived from human peripheral blood cells cultured on plastic 
has also shown that treatment with MCSF and RANKL increased oxygen consumption, as 
well as the expression of mitochondrial respiratory chain enzymes.  Rotenone and 
oligomycin (an ATP synthase inhibitor) both reduced oxygen consumption.  When cells were 
cultured on collagen-coated surfaces, as an attempt to model bone resorption, replacement 
of glucose with galactose (which would be expected to reduce glycolytic flux) somewhat 
reduced collagen degradation, whereas rotenone slightly enhanced it.  Confocal microscopy 
indicated that the glycolytic enzymes PKM2 and GAPDH localise at the sealing zone, close to 
the actin ring, suggesting the possibility that localised glycolysis could allow for rapid, 
effective generation and delivery of ATP for motility (and to power the vacuolar H+ pump) 
during resorption.  The overall conclusion was that oxidative phosphorylation was the main 
bioenergetic source for osteoclast formation, whereas ‘bone resorption’ mainly relied on 
glycolysis [40].     
AMP-activated protein kinase (AMPK) is a key regulator of systemic and cellular energy 
homeostasis whose broad actions are to inhibit energy (eg, ATP) consumption and stimulate 
energy production; it may be considered as a sensor of metabolic stress.  Somewhat 
conflicting results have been published on the role of AMPK in regulating osteoclast 
function.  The AMPK activator, AICA-riboside strongly stimulated OC differentiation in vitro 
and caused profound bone loss in mice in vivo; however, germline deletion of AMPK 
subunits in mice reduced bone mass without any effects on osteoclast numbers in 
trabecular bone, suggesting that AMPK is not required for osteoclast formation [56].  In 
contrast, other groups reported that inactivation of AMPK by siRNA knockdown or deletion 
of its catalytic subunits increased osteoclastogenesis in vitro [38,28,17] and reduced bone 
mass in vivo [28], whereas chemical activation reduced osteoclast numbers and resorption 
in vitro [39] and in vivo [40].   Another ‘energy sensor’ of current interest in osteoclast 
biology is mTORC1 (mechanistic target of rapamycin complex 1), a highly conserved 
intracellular regulatory complex.  Again, current understanding is far from clear.  Inhibition 
of mTOR with rapamycin is reported to significantly reduce osteoclastogenesis [63].  In 
apparent contrast, genetically targeted inhibition or activation of mTORC1 in mouse 
osteoclast precursors are stated to strongly increase or decrease osteoclast differentiation 
and function, respectively [72]. 
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Osteoclast regulation by products of metabolism 
Various metabolic products or by-products are known to exert direct actions on osteoclast 
function.  The most significant such factor appears to be H+ ions, the universal by-product of 
cellular metabolism.  Extracellular acidification has long been known to be an obligatory 
requirement for the activation of osteoclasts, which exhibit little or no resorption pit 
formation at normal blood pH (7.4) [3].  Acidification also acts as a signal to halt the 
precursor cell fusion during osteoclastogenesis [51].  The great sensitivity of osteoclasts to 
small pH changes poses technical challenges when assessing responses to other factors that 
themselves might affect local pH.   The pH response of osteoclasts is also modulated by CO2 
and HCO3
-, such that osteoclasts appear to show particular sensitivity to CO2 acidosis [4].    
Reactive oxygen species (ROS; predominantly H2O2 and superoxide) are produced in the 
mitochondria during generation of ATP [32,10] and play important roles in the function of 
cells in the monocyte-macrophage-osteoclast lineage.   ROS is also generated by TRAP in 
osteoclasts and is thought to contribute to the vesicular degradation of organic matrix [66].  
Numerous studies over the last quarter century have indicated that exogenous ROS [18,8] or 
endogenous ROS [62,37] may stimulate both the formation and resorptive activity of 
osteoclasts, possibly via activation of the NFB pathway, although the details remain far 
from clear [10].    
Pyruvate has been shown to boost oxygen consumption by non-resorbing osteoclasts 
formed from mouse marrow cells [30] and to stimulate the formation of osteoclast-like cells 
in RAW 264.7 cultures [17].  Lactate is reported to exert reprogramming effects on dendritic 
cells [47] but its effects on osteoclasts are unknown. 
Lastly, the intracellular currency of energy, ATP (whose concentration inside cells is 
generally in the range 2-5 mM) is released in small amounts into the extracellular 
environment by osteoblasts and osteoclasts, where it acts on P2 receptors in an autocrine 
or paracrine fashion to modulate cell function [49,50,52,53].  At concentrations near the 
likely physiological range, ATP is a potent stimulator of both the formation and activity of 
rodent osteoclasts, whereas at higher concentrations, it is inhibitory [44,50,42].    
Metabolic adaptation of osteoclasts to hypoxia 
Cells respond to changes in pO2 via oxygen-dependent degradation of hypoxia inducible 
transcription factors (HIFs), a heterodimer containing α and β subunits.  In the presence of 
oxygen, conserved proline residues on HIF-1α, and the closely related HIF-2α are 
hydroxylated by prolyl hydroxylases, targeting them for proteasomal degradation.  In the 
absence of sufficient oxygen, the prolyl hydroxylases are inactive and the proline residues 
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on HIF-α remain unmodified; HIF-α is stabilised and heterodimerises with its transcription 
partner, HIF-β.  The HIF heterodimer binds hypoxia response elements in target gene 
promoters and initiates transcription of hundreds of hypoxia-regulated genes involved in a 
multiplicity of cellular processes [59,27]. 
Stabilised expression of both HIF-1α and HIF-2α, with nuclear translocation, has been 
described in response to hypoxia or the hypoxia mimetic, CoCl2 in mature human 
osteoclasts and their mononuclear progenitor cells [65,32].   Knockdown of HIF-1α is 
reported to abolish resorption pit formation in normoxic cultures of osteoclast-forming 
mouse marrow cells [24].   HIF-1α knockdown has also been shown to inhibit resorption in 
hypoxic cultures of human peripheral blood mononuclear cells [31, 32], whereas induction 
of HIF-1α increased their resorptive activity [22].  However, the aforementioned study failed 
to show a significant regulatory action of HIF-1α on osteoclastogenesis.   HIF-1α expression 
appears to be regulated by estradiol and estrogen receptor-α (ER-α).  In hypoxic cultures of 
osteoclast-like RAW 264.7 cells, estradiol destabilised HIF-1α expression and, in vivo, 
osteoclast-specific HIF-1α inactivation antagonised bone loss in mice that were 
ovariectomised or lacking ER-α in their osteoclasts [41].  
The HIF-mediated adaptation of cells to hypoxia normally necessitates switching to 
anaerobic metabolism to generate the ATP needed for their function and survival.  The 
typical cellular responses to hypoxia entail: 1) increasing the efficiency of complex IV of the 
mitochondrial electron transport chain; 2) upregulation of the cytochrome c oxidase subunit 
COX4-2 at the expense of the COX4-1 subunit; 3) increased expression of glucose 
transporters and glycolytic enzymes; 4) inhibition of mitochondrial pyruvate dehydrogenase, 
thus blocking the tricarboxylic acid cycle; 5) initiation of mitophagy.  A key reason for 
inhibition of mitochondrial ATP production in hypoxia is to reduce the associated generation 
of excess cytotoxic ROS [59,32]. 
The adaptive responses of osteoclasts to hypoxia are potentially somewhat less clear-cut 
because, like macrophages [58] they appear to exhibit a significant basal glycolysis rate 
during differentiation even in normoxic conditions [30,24,1], a situation analogous to the 
‘Warburg effect’ in cancer cells [56,11].   In line with the striking increases in osteoclast 
formation and associated resorption pit formation observed in hypoxia, Knowles and 
colleagues showed that 24 hours exposure of human osteoclasts to a 2% oxygen 
atmosphere increased ATP production, with stimulation of both oxygen consumption and 
expression of COX4-2 mRNA (indices of mitochondrial activity), as well as increased glucose 
consumption and lactate production (indices of glycolytic flux).  Glucose was necessary for 
the hypoxic increase in ATP production and also for cell survival in hypoxia.  Overall, these 
atypical, HIF-1α -mediated metabolic responses were interpreted as facilitating the short-
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term, high metabolic activity of osteoclasts, at the expense of long-term survival [45] – a 
process that could be summarised as ‘live fast, die young’.   
The evident reliance of osteoclasts on anaerobic metabolism suggests possibilities for new 
antiresorptives, and may help explain why imatinib, a c-Abl tyrosine kinase inhibitor that 
suppresses glycolysis can decrease bone resorption in vitro and in vivo [2,13,54].    
Conclusions 
Osteoclasts show impressive metabolic flexibility that enables them to function in diverse 
and sometimes hostile conditions.  These remarkable cells are ultimately responsible for the 
majority of bone pathologies but our understanding their special metabolic characteristics 
remains quite limited.  Although it seems clear that osteoclasts can switch to glycolysis in 
hypoxia, the extent to which they may also rely on anaerobic metabolism in ‘normoxic’ (or 
even hyperoxic) environments to support their formation, motility and resorptive activity is 
still unclear.  The mechanism by which osteoclastogenesis is promoted by hypoxia 
additionally needs clarification, since it does not appear to be significantly dependent on 
HIF-1α (and, theoretically might even be driven by re-oxygenation).  The reasons for the 
striking numbers of mitochondria in osteoclasts also need further examination. 
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Fig 1.   Scanning electron micrograph showing the extensive resorption area (pink) 
associated with a large osteoclast (blue) formed from mouse marrow cultured in the 
presence of M-CSF and RANKL on an ivory slice, and activated for 48 hours in acidified (pH 
7.0) medium.   Field width = 85 µm.    
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Fig 2.   Transmission electron micrographs showing an osteoclast with 4 or 5 nuclei (N) and 
ruffled border (RB), actively resorbing bone.   Lower panel is an enlargement of boxed area 
in upper panel, showing abundant mitochondria (M).  Field width of upper panel = 35 µm.  
By kind permission of E. McDermott and M.H. Helfrich, University of Aberdeen. 
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Fig 3.   Simplified summary of aerobic and anaerobic metabolism in osteoclasts.  GLUT-1, 
glucose transporter; TCA, tricarboxylic acid; MIT ETC, mitochondrial electron transport 
chain; ROS, reactive oxygen species; v-ATPase, vacuolar H+ proton pump. 
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Metabolic properties of the osteoclast – Arnett & Orriss 
 
 
 
Highlights 
 Resorption of bone by osteoclasts is rapid and energy-intensive (utilises glucose) 
 Osteoclasts contain many mitochondria but also generate ATP anaerobically 
 Resorptive function of osteoclasts is unimpaired in hypoxia 
 Osteoclastogenesis (& thus resorption) is strongly enhanced by intermittent hypoxia 
 Chronic hypoxia may promote osteoclast apoptosis via ROS build-up in mitochondria 
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